Hua Gao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1571025/publications.pdf Version: 2024-02-01



Hun Cao

#	Article	IF	CITATIONS
1	A New Accurate, Simple and Less Radiation Exposure Device for Distal Locking of Femoral Intramedullary Nails. International Journal of General Medicine, 2021, Volume 14, 4145-4153.	0.8	5
2	Obesity regulates miRâ€467/HoxA10 axis on osteogenic differentiation and fracture healing by BMSCâ€derived exosome LncRNA H19. Journal of Cellular and Molecular Medicine, 2021, 25, 1712-1724.	1.6	28
3	Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype. Aging, 2021, 13, 1276-1293.	1.4	7
4	Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors. Aging, 2021, 13, 1422-1439.	1.4	2
5	JAG1, Regulated by microRNA-424-3p, Involved in Tumorigenesis and Epithelial–Mesenchymal Transition of High Proliferative Potential-Pituitary Adenomas. Frontiers in Oncology, 2020, 10, 567021.	1.3	9
6	Clinical and functional comparison of dynamic hip screws and intramedullary nails for treating proximal femur metastases in older individuals. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 395-402.	0.7	1
7	CDKN2A (p16INK4A) affects the anti‑tumor effect of CDK inhibitor in somatotroph adenomas. International Journal of Molecular Medicine, 2020, 47, 500-510.	1.8	5
8	ldentification of Serum miRNA-423-5p Expression Signature in Somatotroph Adenomas. International Journal of Endocrinology, 2019, 2019, 1-12.	0.6	30
9	The Apoptosis Regulator 14-3-3η and Its Potential as a Therapeutic Target in Pituitary Oncocytoma. Frontiers in Endocrinology, 2019, 10, 797.	1.5	10
10	Metabolic profiling reveals distinct metabolic alterations in different subtypes of pituitary adenomas and confers therapeutic targets. Journal of Translational Medicine, 2019, 17, 291.	1.8	9
11	DAPT, a Î ³ -Secretase Inhibitor, Suppresses Tumorigenesis, and Progression of Growth Hormone-Producing Adenomas by Targeting Notch Signaling. Frontiers in Oncology, 2019, 9, 809.	1.3	31
12	Impact of SLC20A1 on the Wnt/βâ€ʿcatenin signaling pathway in somatotroph adenomas. Molecular Medicine Reports, 2019, 20, 3276-3284.	1.1	8
13	High-Dose Neural Stem/Progenitor Cell Transplantation Increases Engraftment and Neuronal Distribution and Promotes Functional Recovery in Rats after Acutely Severe Spinal Cord Injury. Stem Cells International, 2019, 2019, 1-17.	1.2	8
14	Expression of Cyclin E/Cdk2/p27Kip1 in Growth Hormone Adenomas. World Neurosurgery, 2019, 121, e45-e53.	0.7	7
15	Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis. Open Chemistry, 2019, 17, 1501-1508.	1.0	Ο
16	Attenuation of EGFL7 Expression Inhibits Growth Hormone–Producing Pituitary Adenomas Growth and Invasion. Human Gene Therapy, 2018, 29, 1396-1406.	1.4	6
17	P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma. Journal of Neuro-Oncology, 2018, 136, 485-494.	1.4	4
18	Analysis of clinical factors and PDGFR-Î ² in predicting prognosis of patients with clival chordoma. Journal of Neurosurgery, 2018, 129, 1429-1437.	0.9	19

Hua Gao

#	Article	IF	CITATIONS
19	The Effects of Smad3 on Adrenocorticotropic Hormone–Secreting Pituitary Adenoma Development, Cell Proliferation, Apoptosis, and Hormone Secretion. World Neurosurgery, 2018, 114, e329-e337.	0.7	7
20	Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas. Molecular and Cellular Endocrinology, 2018, 474, 168-175.	1.6	18
21	SNF5 as a prognostic factor in skull base chordoma. Journal of Neuro-Oncology, 2018, 137, 139-146.	1.4	14
22	Epithelial–Mesenchymal Transition Induced by SMAD4 Activation in Invasive Growth Hormone-Secreting Adenomas. Open Chemistry, 2018, 16, 571-582.	1.0	3
23	Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion. Open Chemistry, 2018, 16, 621-626.	1.0	1
24	A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. Oncology Reports, 2018, 41, 113-124.	1.2	9
25	Association of TGF-β1 and WIF1 Expression with 36 Paired Primary/Recurrent Nonfunctioning Pituitary Adenomas: A High-Throughput Tissue Microarrays Immunohistochemical Study. World Neurosurgery, 2018, 119, e23-e31.	0.7	4
26	Neuro-endoscope for skull base tumors. Clinical Neurology and Neurosurgery, 2018, 170, 102-105.	0.6	7
27	Role of EGFL7/EGFR-signaling pathway in migration and invasion of growth hormone-producing pituitary adenomas. Science China Life Sciences, 2018, 61, 893-901.	2.3	16
28	Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas. Clinical Cancer Research, 2018, 24, 5757-5766.	3.2	43
29	Analysis of Ki67, HMCA1, MDM2, and RB expression in nonfunctioning pituitary adenomas. Journal of Neuro-Oncology, 2017, 132, 199-206.	1.4	18
30	Evaluation of Singh Index and Osteoporosis Self-Assessment Tool for Asians as risk assessment tools of hip fracture in patients with type 2 diabetes mellitus. Journal of Orthopaedic Surgery and Research, 2017, 12, 37.	0.9	20
31	Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes. Oncology Letters, 2017, 13, 4533-4539.	0.8	3
32	Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas. World Neurosurgery, 2017, 99, 282-287.	0.7	4
33	ESR1 and its antagonist fulvestrant in pituitary adenomas. Molecular and Cellular Endocrinology, 2017, 443, 32-41.	1.6	23
34	Long non-coding RNA C5orf66-AS1 is downregulated in pituitary null cell adenomas and is associated with their invasiveness. Oncology Reports, 2017, 38, 1140-1148.	1.2	30
35	EGFL7 participates in regulating biological behavior of growth hormone–secreting pituitary adenomas via Notch2/DLL3 signaling pathway. Tumor Biology, 2017, 39, 101042831770620.	0.8	32
36	Plate Fixation Versus Intramedullary Nailing for Bothâ€Bone Forearm Fractures: A Metaâ€analysis of Randomized Controlled Trials and Cohort Studies. World Journal of Surgery, 2017, 41, 722-733.	0.8	27

Hua Gao

#	Article	IF	CITATIONS
37	Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas. World Neurosurgery, 2017, 98, 323-328.	0.7	17
38	Use of micro-positron emission tomography with 18F-fallypride to measure the levels of dopamine receptor-D2 and 18F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats. OncoTargets and Therapy, 2016, 9, 2057.	1.0	2
39	Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas. Oncology Reports, 2016, 35, 2991-2999.	1.2	3
40	Whole-exome sequencing identifies variants in invasive pituitary adenomas. Oncology Letters, 2016, 12, 2319-2328.	0.8	26
41	The role of FSCN1 in migration and invasion of pituitary adenomas. Molecular and Cellular Endocrinology, 2016, 419, 217-224.	1.6	40
42	Clinical and functional comparison of endoprosthetic replacement with intramedullary nailing for treating proximal femur metastasis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 209-214.	0.7	16
43	Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer, 2015, 15, 272.	1.1	34
44	Maffucci syndrome with unilateral limb: a case report and review of the literature. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 254-8.	0.7	12